World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0026637162
Reproduction Date:

Title: Sarizotan  
Author: World Heritage Encyclopedia
Language: English
Subject: Osemozotan, Fananserin, WAY-100,635, AS-8112, Spiroxatrine
Collection: Abandoned Drugs, Amines, Chromanes, Organofluorides, Pyridines
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Pregnancy cat.
  • N/A
Legal status
  • Discontinued
Routes Oral
CAS number
ATC code None
Chemical data
Formula C22H21FN2O 
Mol. mass 348.413 g/mol

Sarizotan (EMD-128,130) is a selective 5-HT1A receptor agonist and D2 receptor antagonist,[1] which has antipsychotic effects,[2][3] and has also shown efficacy in reducing dyskinesias resulting from long-term anti-Parkinsonian treatment with levodopa.[4][5][6][7]

In June 2006, the developer Merck KGaA announced that the development of sarizotan was discontinued, after two sarizotan Phase III studies (PADDY I, PADDY II) failed to meet the primary efficacy endpoint and neither the Phase II findings nor the results from preclinical studies could be confirmed. No statistically significant difference of the primary target variable between sarizotan and placebo could be demonstrated.[8][9]

See also


  1. ^ Rabiner, E. A.; Gunn, R. N.; Wilkins, M. R.; Sedman, E.; Grasby, P. M. (2002). "Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with 11CWAY-100635 and 11Craclopride". Journal of psychopharmacology (Oxford, England) 16 (3): 195–199.  
  2. ^ Assié, M.; Ravailhe, V.; Faucillon, V.; Newman-Tancredi, A. (2005). "Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain". The Journal of Pharmacology and Experimental Therapeutics 315 (1): 265–272.  
  3. ^ Auclair, A.; Galinier, A.; Besnard, J.; Newman-Tancredi, A.; Depoortère, R. (2007). "Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats". Psychopharmacology 193 (1): 45–54.  
  4. ^ Bibbiani, F.; Oh, J. D.; Chase, T. N. (2001). "Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models". Neurology 57 (10): 1829–1834.  
  5. ^ Bartoszyk, G.; Van Amsterdam, C.; Greiner, H.; Rautenberg, W.; Russ, H.; Seyfried, C. (2004). "Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile". Journal of neural transmission (Vienna, Austria : 1996) 111 (2): 113–126.  
  6. ^ Bara-Jimenez, W.; Bibbiani, F.; Morris, M.; Dimitrova, T.; Sherzai, A.; Mouradian, M.; Chase, T. (2005). "Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease". Movement disorders : official journal of the Movement Disorder Society 20 (8): 932–936.  
  7. ^ Grégoire, L.; Samadi, P.; Graham, J.; Bédard, P.; Bartoszyk, G.; Di Paolo, T. (2009). "Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys". Parkinsonism & related disorders 15 (6): 445–452.  
  8. ^ "Merck KGaA: Development of Sarizotan to treat Parkinson's patients will not be pursued". Ad Hoc News. 23 June 2006. 
  9. ^ "Merck KGaA discontinues development of Parkinson drug Sarizotan UPDATE". Forbes. 23 June 2006. 

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.